Suzhou Fushilai Pharmaceutical Stock Revenue
| 301258 Stock | 23.30 0.06 0.26% |
Suzhou Fushilai Pharmaceutical fundamentals help investors to digest information that contributes to Suzhou Fushilai's financial success or failures. It also enables traders to predict the movement of Suzhou Stock. The fundamental analysis module provides a way to measure Suzhou Fushilai's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Suzhou Fushilai stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 562.7 M | 551.9 M |
Suzhou | Revenue |
Suzhou Fushilai Pharmaceutical Company Revenue Analysis
Suzhou Fushilai's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Suzhou Fushilai Revenue | 489.29 M |
Most of Suzhou Fushilai's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Suzhou Fushilai Pharmaceutical is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Suzhou Total Revenue
Total Revenue |
|
Based on the latest financial disclosure, Suzhou Fushilai Pharmaceutical reported 489.29 M of revenue. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The revenue for all China stocks is notably lower than that of the firm.
Suzhou Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Suzhou Fushilai's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Suzhou Fushilai could also be used in its relative valuation, which is a method of valuing Suzhou Fushilai by comparing valuation metrics of similar companies.Suzhou Fushilai is currently under evaluation in revenue category among its peers.
Suzhou Fundamentals
| Return On Equity | 0.0099 | ||||
| Return On Asset | -0.0028 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | (0.05) % | ||||
| Current Valuation | 754.12 M | ||||
| Shares Outstanding | 91.67 M | ||||
| Shares Owned By Insiders | 66.20 % | ||||
| Shares Owned By Institutions | 1.07 % | ||||
| Price To Book | 1.13 X | ||||
| Price To Sales | 5.17 X | ||||
| Revenue | 489.29 M | ||||
| Gross Profit | 88.02 M | ||||
| EBITDA | 49 M | ||||
| Net Income | 112.18 M | ||||
| Total Debt | 170.45 M | ||||
| Book Value Per Share | 20.77 X | ||||
| Cash Flow From Operations | 94.77 M | ||||
| Earnings Per Share | 0.20 X | ||||
| Number Of Employees | 544 | ||||
| Beta | 0.53 | ||||
| Market Capitalization | 2.14 B | ||||
| Total Asset | 2.12 B | ||||
| Retained Earnings | 663.54 M | ||||
| Working Capital | 1.54 B | ||||
| Annual Yield | 0.03 % | ||||
| Net Asset | 2.12 B | ||||
| Last Dividend Paid | 0.6 |
About Suzhou Fushilai Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Suzhou Fushilai Pharmaceutical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Suzhou Fushilai using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Suzhou Fushilai Pharmaceutical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Suzhou Stock
Suzhou Fushilai financial ratios help investors to determine whether Suzhou Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Suzhou with respect to the benefits of owning Suzhou Fushilai security.